Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05464069 · ClinicalTrials.gov registry record
Safety of Nerivio in Pregnant Women With Migraine
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 145
- Enrollment target
NCT05464069: Completed study, sponsored by Theranica.
NCT05464069 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05464069 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica's user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is based on an e-Survey including an e-eligibility questionnaire, an e-ICF ande-Questionnaire. Participants will be compensated for their time.
Primary Outcome
The mean number of gestational age at delivery in both study groups (measured in pregnancy days).
Interventions
- DEVICE Nerivio
- DRUG Migraine Relief
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2022-12-07 |
What the finished NCT05464069 record still lists
NCT05464069 is an observational study that tracks outcomes without assigning an intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Nerivio is the first listed.
NCT05464069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05464069 about?
NCT05464069 is a clinical study titled "Safety of Nerivio in Pregnant Women With Migraine". This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with...
What is the current status of trial NCT05464069?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2022-08-01. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT05464069?
The interventions under investigation include: Nerivio (DEVICE), Migraine Relief (DRUG).
Who is sponsoring clinical trial NCT05464069?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI